Researchers at University Putra Malaysia found a relationship between some markers of inflammation in the body and the aggressiveness of certain malignant tumors. They conducted full body scans of 31 people with malignant tumors—including cancers of the lung, esophagus, colon and breast—using a machine that combines positron emission and computed tomography (PET/CT). The scans evaluated tumor malignancy and aggressiveness based on a measurement, called the maximum standardized uptake value (SUVmax). {read more here}

“Basically, we attach the imaging radionuclide to the peptide, then the radiolabeled peptide finds MC1Rs on the melanoma through blood circulation, allowing us to use a PET machine to gather the signals from the radiolabeled peptide for melanoma imaging. It’s a very sensitive way to see melanoma,” says Yubin Miao, Ph.D., investigator at CU Cancer Center and Director of Radiopharmaceutical Science at the Radiology of CU School of Medicine. {read more here}

In a cohort of 77 participants in the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Aging, who were considered cognitively healthy at baseline yet at risk for AD, a higher baseline score for overall MeDi adherence was significantly associated with less Aβ accumulation, as shown on positron emission tomography (PET). {read more here}

Using advanced imaging to predict the likelihood of a malignant brain tumor recurring after radiation treatment could enable creation of a more effective treatment plan. With this aim, researchers at the University of Copenhagen have developed a model that uses pre-treatment PET and MRI to create patient-specific maps of recurrence probability for glioblastoma tumors.  {read more here}